Low sclerostin levels after long-term remission of acromegaly
| Autor: | Antoon H van Lierop, Alberto M. Pereira, Herman M. Kroon, Natasha M. Appelman-Dijkstra, Kim M J A Claessen, Nienke R. Biermasz, Iris C. M. Pelsma |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Sclerostin Endocrinology Diabetes and Metabolism Population Osteoporosis Gastroenterology chemistry.chemical_compound Absorptiometry Photon Endocrinology Bone Density Internal medicine Diabetes mellitus Acromegaly medicine Humans Insulin-Like Growth Factor I education Adaptor Proteins Signal Transducing Aged Bone mineral education.field_of_study Human Growth Hormone business.industry Plasma levels Middle Aged medicine.disease Insulin-like growth factor-1 chemistry Bone microstructure Vertebral fractures Spinal Fractures Female Original Article Long term remission business |
| Zdroj: | Endocrine Endocrine, 75, 228-238. SPRINGER |
| Popis: | Purpose Bone health is compromised in acromegaly resulting in vertebral fractures (VFs), regardless of biochemical remission. Sclerostin is a negative inhibitor of bone formation and is associated with increased fracture risk in the general population. Therefore, we compared sclerostin concentrations between well-controlled acromegaly patients and healthy controls, and assessed its relationship with bone mineral density (BMD), and VFs in acromegaly. Methods Seventy-nine patients (mean age 58.9 ± 11.4 years, 49% women) with controlled acromegaly, and 91 healthy controls (mean age 51.1 ± 16.9 years, 59% women) were included. Plasma sclerostin levels (pg/mL) in patients were measured with an ELISA assay, whereas in controls, serum levels were converted to plasma levels by multiplication with 3.6. In patients, VFs were radiographically assessed, and BMD was assessed using dual X-ray absorptiometry. Results Median sclerostin concentration in controlled acromegaly patients was significantly lower than in healthy controls (104.5 pg/mL (range 45.7–234.7 pg/mL) vs 140.0 pg/mL (range 44.8–401.6 pg/mL), p Conclusion Patients with long-term controlled acromegaly have lower plasma sclerostin levels than healthy controls, as a reflection of decreased osteocyte activity. Further longitudinal studies are needed to establish the course of sclerostin during different phases of disease and its exact effects in acromegalic osteopathy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|